Industry updates from the field of stem cell research and regenerative medicine in August 2022
Abstract
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in August 2022.
Tweetable abstract
Regenerative medicine industry news digest, August 2022.
References
- 1. Poseida Therapeutics. Poseida Therapeutics announces strategic global collaboration with roche focused on allogeneic CAR-T cell therapies for hematologic malignancies. (2022). https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-announces-strategic-global-collaboration
- 2. ElevateBio. ElevateBio partners with the California Institute for Regenerative Medicine to accelerate the development of regenerative medicines. (2022). www.elevate.bio/press-releases/elevatebio-partners-with-the-california-institute-for-regenerative-medicine-to-accelerate-the-development-of-regenerative-medicines
- 3. ElevateBio. ElevateBio and the University of Pittsburgh announce creation of Pitt BioForge BioManufacturing center at Hazelwood Green to accelerate cell and gene therapy innovation. (2022). www.elevate.bio/press-releases/elevatebio-and-the-university-of-pittsburgh-announce-creation-of-pitt-bioforge-biomanufacturing-center-at-hazelwood-green-to-accelerate-cell-and-gene-therapy-innovation
- 4. ElevateBio. ElevateBio announces the formation of a new company with George Daley, M.D., Ph.D., and Boston Children's Hospital to develop iPSC-derived allogeneic immune therapies. (2022). www.elevate.bio/press-releases/elevatebio-announces-the-formation-of-a-new-company-with-george-daley-m-d-ph-d-and-boston-childrens-hospital-to-develop-ipsc-derived-allogeneic-immune-therapies
- 5. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell 29, 1181–1196 (2022).
- 6. PRNewswire. Regen BioPharma develops novel means of using CAR-T cell immunotherapy to attack solid tumors. (2022). www.prnewswire.com/news-releases/regen-biopharma-develops-novel-means-of-using-car-t-cell-immunotherapy-to-attack-solid-tumors-301612726.html
- 7. . An eye implant engineered from proteins in pigskin restored sight in 14 blind people. NBC News (2022). www.nbcnews.com/health/health-news/eye-implant-pig-protein-restored-sight-blind-people-rcna42681
- 8. Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts. Nat. Biotechnol. (2022)
doi: 0.1038/s41587-022-01408-w (Epub ahead of print). - 9. NCT04653922. Evaluation of safety and efficacy of a bioengineered corneal implant for treatment of keratoconus (LinkCor). (2022). https://clinicaltrials.gov/ct2/show/NCT04653922
- 10. Post-gastrulation synthetic embryos generated ex utero from mouse naive ESCs. Cell 185, 3290–3306 (2022).
- 11. . Mouse stem cells grown into embryo mimics. Science 377, 565–566 (2022).
- 12. Voice of America News. ‘Synthetic embryo’ breakthrough but growing human organs far off. (2022). www.voanews.com/a/synthetic-embryo-breakthrough-but-growing-human-organs-far-off-/6688670.html
- 13. . First synthetic embryos: the scientific breakthrough raises serious ethical questions. The conversation. (2022). https://theconversation.com/first-synthetic-embryos-the-scientific-breakthrough-raises-serious-ethical-questions-188382
- 14. Graphite Bio. Graphite Bio doses first patient with investigational gene editing therapy GPH101 for sickle cell disease. (2022). https://ir.graphitebio.com/press-releases/detail/76/graphite-bio-doses-first-patient-with-investigational-gene
- 15. NCT04819841. Gene correction in autologous CD34+ hematopoietic stem cells (HbS to HbA) to treat severe sickle cell disease (CEDAR). (2022). https://clinicaltrials.gov/ct2/show/NCT04819841
- 16. Gamida Cell. Gamida cell announces dosing of first patient in company-sponsored Phase I/II study of NK cell therapy candidate GDA-201. (2022). https://investors.gamida-cell.com/node/8876/pdf
- 17. NCT05296525. Evaluation of safety and efficacy of Allo GDA-201 NK cells in patients with relapsed/refractory B cell NHL. (2022). https://clinicaltrials.gov/ct2/show/NCT05296525
- 18. Innovative Cellular Therapeutics. Innovative Cellular Therapeutics (ICT) announces first patient enrolled for the company's Phase I trial of GCC19CART for relapsed/refractory metastatic colorectal cancer. (2022). www.ictbio.com/news/innovative-cellular-therapeutics-ict-announces-first-patient-enrolled-for-the-companys-phase-i-trial-of-gcc19cart-for-relapsed-refractory-metastatic-colorectal-cancer/
- 19. NCT05319314. GCC19CART for patients with metastatic colorectal cancer (CARAPIA-1). (2022). https://clinicaltrials.gov/ct2/show/NCT05319314
- 20. Orca Bio. Orca Bio announces the precision-T Phase III study is open and enrolling patients at transplant centers across the U.S.. (2022). https://orcabio.com/2022-08-02/
- 21. NCT05316701. Precision-T: a randomized Phase III study of Orca-T in recipients undergoing allogeneic transplantation for hematologic malignancies (Orca-T). (2022). https://clinicaltrials.gov/ct2/show/NCT05316701
- 22. Lykan Bioscience. RoslinCT And Lykan Bioscience combine to create leading advanced cell therapy CDMO. (2022). www.lykanbio.com/roslinct-and-lykan-bioscience-combine-to-create-leading-advanced-cell-therapy-cdmo/
- 23. bluebird bio. bluebird bio announces FDA approval of ZYNTEGLO®, the first gene therapy for people with beta-thalassemia who require regular red blood cell transfusions. (2022). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy
- 24. bluebird bio. bluebird bio announces U.S. commercial infrastructure to enable patient access to ZYNTEGLO®, the first and only FDA-approved gene therapy for people with beta-thalassemia who require regular red blood cell Transfusions. (2022). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-us-commercial-infrastructure-enable
- 25. Calidi Biotherapeutics. Calidi Biotherapeutics announces FDA authorization of IND for a Phase I clinical trial of NeuroNova in patients with recurrent high-grade glioma. (2022). https://calidibio.com/2022/08/02/calidi-biotherapeutics-announces-fda-authorization-of-ind-for-a-phase-1-clinical-trial-of-neuronova-in-patients-with-recurrent-high-grade-glioma/
- 26. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, Phase I, dose-escalation trial. Lancet Oncol. 22, 1103–1114 (2021).
- 27. Cellectis. Cellectis receives IND clearance for UCART20x22, its first in-house manufactured product candidate for the treatment of B-cell malignancies. (2022). https://cellectis.com/en/press/cellectis-receives-ind-clearance-for-ucart20x22-its-first-in-house-manufactured-product-candidate-for-the-treatment-of-b-cell-malignancies/
- 28. Celyad. Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase Ib trial. (2022). https://celyad.com/wp-content/uploads/Keynote-CYAD-FDA-Clinical-Hold_EN.pdf
- 29. Century Therapeutics. Century Therapeutics receives study may proceed notification from FDA for CNTY-101, the first allogeneic cell therapy product candidate engineered to overcome three major pathways of host vs graft rejection. (2022). https://investors.centurytx.com/node/7291/pdf
- 30. NCT05336409. A study of CNTY-101 in participants with CD19-positive B-cell malignancies (ELiPSE-1). (2022). https://clinicaltrials.gov/ct2/show/NCT05336409
- 31. Charles River Laboratories. Charles River Laboratories is first CDMO in North America to receive EMA approval to commercially produce an allogeneic cell therapy drug product. (2022). https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-first-cdmo-north-america-receive-ema
- 32. Foundation for the Accreditation of Cellular Therapy (FACT). King Abdulaziz Medical City – Riyadh, Saudi Arabia is first cellular therapy program in Saudi Arabia to earn FACT accreditation. (2022). www.factglobal.org/media/h3afisiu/king-abdulaziz-medical-city-riyadh-saudi-arabia-08-16-22.pdf
- 33. 3T Biosciences. 3T biosciences debuts with $40 million series a financing. (2022). https://3tbiosciences.com/3t-biosciences-debuts-with-40-million-series-a-financing/
- 34. Poseida Therapeutics. Poseida Therapeutics announces proposed public offering of common stock. (2022). https://investors.poseida.com/node/8021/pdf
- 35. Poseida Therapeutics. Poseida Therapeutics announces pricing of public offering of common stock. (2022). https://investors.poseida.com/node/8036/pdf
- 36. Poseida Therapeutics. Poseida Therapeutics announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares. (2022). https://investors.poseida.com/node/8056/pdf